

*REMARKS*

*The Present Invention and Pending Claims*

Claim 3 is pending and directed to a nucleotide sequence of mutant protein kinase regulatory subunit 1A gene.

*The Amendments to the Claims*

Claim 3 has been amended to remove non-elected subject matter. Applicants reserve the right to pursue any canceled subject matter in a continuation, continuation-in-part, divisional application, or other application. Cancellation of any subject matter should not be construed as abandonment of that subject matter.


*The Office Action and Discussion of Applicants' Response*

The Office has required the cancellation of non-elected subject matter in claim 3. Applicants have removed reference to SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:36, SEQ ID NO:44, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:53, SEQ ID NO:56, SEQ ID NO:57, and SEQ ID NO:60 from claim 3. Accordingly, Applicants believe that the claim has been properly amended to place the application in condition for allowance.

*Conclusion*

The application is considered to be in good and proper form for allowance, and the Examiner is respectfully requested to pass this application to issue. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



---

Carol Larcher, Reg. No. 35,243  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6780  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: December 12, 2003